American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Hassoun
    Hassoun
  3. Hultcrantz
    Hultcrantz
  4. Lesokhin
    Lesokhin
  5. Mailankody
    Mailankody
  6. Patel
    Patel
  7. Shah
    Shah
  8. Tan
    Tan
  9. Korde
    Korde
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (22)
  2. Department of Medicine (22)
  3. General Medicine Services (22)
  4. Hematologic Malignancies, Division of (22)
  5. Hospital Medicine (22)
  6. Bone Marrow Transplant (21)
  7. CTCR Scholars (21)
  8. Hematologic Malignancies Research (21)
  9. Myeloma (21)
  10. Sloan Kettering Institute Postdocs (21)
Search Within
  1. "Hospital Medicine"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (2)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (22)
  2. Department of Medicine (22)
  3. General Medicine Services (22)
  4. Hematologic Malignancies, Division of (22)
  5. Hospital Medicine (22)
  6. Bone Marrow Transplant (21)

More Groups

People
  1. Alexander Lesokhin (21)
  2. Carlyn Rose Tan (21)
  3. Dhwani Patel (21)
  4. Hani Hassoun (21)
  5. Malin Hultcrantz (21)
  6. Sergio Giralt (21)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (7)
  4. 2022 (4)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publications
  1. Blood (19)
  2. Blood Advances (3)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Journal Article

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M. L.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
    Journal Article

    Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save